Fusion Pharm Net Income
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion Pharm technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fusion Pharm Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -37.9 K | -36 K | |
| Net Loss | -37.9 K | -36 K | |
| Net Loss | -37.9 K | -36 K |
Fusion | Net Income | Build AI portfolio with Fusion Stock |
Evaluating Fusion Pharm's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Fusion Pharm's fundamental strength.
Latest Fusion Pharm's Net Income Growth Pattern
Below is the plot of the Net Income of Fusion Pharm over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fusion Pharm financial statement analysis. It represents the amount of money remaining after all of Fusion Pharm operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fusion Pharm's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fusion Pharm's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (42.08 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Fusion Net Income Regression Statistics
| Arithmetic Mean | (68,819) | |
| Coefficient Of Variation | (106.54) | |
| Mean Deviation | 45,260 | |
| Median | (42,080) | |
| Standard Deviation | 73,319 | |
| Sample Variance | 5.4B | |
| Range | 251.6K | |
| R-Value | 0.53 | |
| Mean Square Error | 4.1B | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | 7,761 | |
| Total Sum of Squares | 86B |
Fusion Net Income History
Other Fundumenentals of Fusion Pharm
Fusion Pharm Net Income component correlations
Click cells to compare fundamentals
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Fusion Pharm 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fusion Pharm's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fusion Pharm.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Fusion Pharm on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Fusion Pharm or generate 0.0% return on investment in Fusion Pharm over 90 days. FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in th... More
Fusion Pharm Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fusion Pharm's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fusion Pharm upside and downside potential and time the market with a certain degree of confidence.
Fusion Pharm Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fusion Pharm's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fusion Pharm's standard deviation. In reality, there are many statistical measures that can use Fusion Pharm historical prices to predict the future Fusion Pharm's volatility.Fusion Pharm Backtested Returns
We have found three technical indicators for Fusion Pharm, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Fusion Pharm are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Fusion Pharm has perfect predictability. Overlapping area represents the amount of predictability between Fusion Pharm time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fusion Pharm price movement. The serial correlation of 1.0 indicates that 100.0% of current Fusion Pharm price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Fusion Pharm reported net income of (42,080). This is 100.01% lower than that of the Consumer Staples Distribution & Retail sector and significantly lower than that of the Consumer Staples industry. The net income for all United States stocks is 100.01% higher than that of the company.
Fusion Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharm's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharm could also be used in its relative valuation, which is a method of valuing Fusion Pharm by comparing valuation metrics of similar companies.Fusion Pharm is currently under evaluation in net income category among its peers.
Fusion Fundamentals
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.63 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 67.01 K | ||||
| Net Income | (42.08 K) | ||||
| Cash And Equivalents | 1.45 K | ||||
| Total Debt | 1.2 K | ||||
| Current Ratio | 0.73 X | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | 239.84 K | ||||
| Earnings Per Share | (0.15) X | ||||
| Beta | 25.84 | ||||
| Market Capitalization | 1.06 K | ||||
| Total Asset | 4.04 K | ||||
| Retained Earnings | (9.11 K) | ||||
| Working Capital | 728 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 459 K | ||||
| Net Asset | 4.04 K |
About Fusion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.